Earnings Call Excerpt
Inverness Medical Innovations, Inc. (IMA)
Q3 2008 Earnings Call
October 29, 2008 10:00 a.m. ET
Executives
Ron Zwanziger – Chairman, Chief Executive Officer, and President
David Teitel – Chief Financial Officer and Principal Accounting Officer
Doug Guarino – Director of Corporate Relations
Analysts
Greg Simpson – Stifel Nicholas and Company, Inc.
Jonathan Goldberg – Merrill Lynch
Peter Bye – Jeffries and Company
[Jeffrey Freelick] – Lazard Capital Markets
Presentation
Operator
Good morning. My name is Barbara and I'll be facilitating the audio portion of today's interactive broadcast. (Operator instructions) At this time, I would like to turn the event over to Doug Guarino. Sir, you may begin.
Doug Guarino
Thank you Barbara and good morning and welcome to the Inverness Medical Innovations conference call to discuss our results for the quarter ended September 30, 2008. We are joined today by Ron Zwanziger, Chairman and CEO, and David Teitel, CFO.
Before we get to that discussion though, I would first like to draw your attention to the fact that certain matters discussed in this conference call will constitute forward-looking statements, within the meaning of the US Securities law. These statements reflect our current views in respect to future events, or financial performance and are based on management’s current assumptions and information currently available. Actual results and the timing of certain events could differ materially from those projected or contemplated by the forward looking statements due to numerous factors including without limitation, our ability to successfully integrate our acquisitions and to recognizing expected benefits of restructuring and new business activities; the performance of businesses acquired, our ability to consummate the health management joint venture alternative arrangements that we are exploring, the impact of the recent crises in the global financial markets including the credit markets, our plans and operations and those of our suppliers and customers; our exposure to changes in interest rates in foreign currency exchange rates; our ability to successfully develop and commercialize products, the market acceptance of our products, continued acceptance of healthy management services by payers, providers, and patients; the content and timing of decisions by regulatory authorities, both in the United States and abroad; the effect of pending and future legal proceedings in our financial performance; and the risks and uncertainties described in our periodic reports filed with the securities and exchange commission, including our form 10K for the year ended December 31, 2007. Our company undertakes no obligation to update forward looking statements. Our company undertakes no obligation to update forward-looking statements.
- To read the full transcript on Seeking Alpha, click here »
